Lipid Nanoparticles at the Crossroads of Chemistry and Medicine: A Tutorial
Summary
Lipid nanoparticles (LNPs) have risen to the forefront of modern therapeutics by enabling the clinical success of COVID-19 mRNA vaccines. In order for them to function as drug delivery vesicles, LNPs must have scalable, tunable, and targeted nanoscale platforms whose strengths in versatility, performance, and clinical relevance are driven by key design parameters and formulation strategies. This Tutorial Review traces the historical evolution of LNPs and examines the fundamental design principles governing their structure, physicochemical properties, and biological behavior.
Keywords
Lipid nanoparticles (LNPs) have risen to the forefront of modern therapeutics by enabling the clinical success of COVID-19 mRNA vaccines. In order for them to function as drug delivery vesicles, LNPs must have scalable, tunable, and targeted nanoscale platforms whose strengths in versatility, performance, and clinical relevance are driven by key design parameters and formulation strategies. This Tutorial Review traces the historical evolution of LNPs and examines the fundamental design principles governing their structure, physicochemical properties, and biological behavior. It further highlights modern analytical characterization techniques that have advanced mechanistic understanding of LNP composition, morphology, and function as well as targeting strategies to improve LNP delivery to extrahepatic sites. Current translational challenges and emerging advances are also discussed. This Tutorial Review provides a framework for understanding the foundations, current landscape, and future directions of LNP research.
Abstract from PubMed Central (PMID 42921289, PMC13692744). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Mathematical modeling in mRNA therapeutics: towards a pathway to individualized treatment protocols
Molecular pharmaceuticsCombined siRNA Targeting IκBα and Stat6 Promotes Macrophage Reprogramming toward Cancer Immunotherapy
The Journal of clinical investigationA single liver-sparing myotropic AAV ameliorates muscular dystrophy in humanized mice by base editing
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
